Perrigo Co. (NYSE: PRGO) announced that its board declared a quarterly dividend of 9 cents per share, payable Dec. 17 to shareholders of record on Nov. 29.
The Allegan generic pharmaceutical and store-brand health products maker Perrigo Co. Ltd., which moved its corporate registration to Ireland earlier this year, said it would offer debt totaling $2.3 billion with maturities in 2016, 2018, 2023 and 2043.
The generic pharmaceutical and store-brand helath products maker Perrigo Co. (NYSE: PRGO) Thursday reported net income of $111.4 million or $1.18 a share in the first fiscal quarter ended Sept. 28, up from $105.6 million or $1.12 a share in the first fiscal quarter a year earlier. Revenue was $933.4 million, up from $769.8 million a year earlier.
Perrigo Co. (NYSE: PRGO) announced that it has scheduled a shareholder meeting for Monday, Nov. 18 in connection with Perrigo’s proposed previously announced acquisition of Elan Corp. (NYSE: ELN).
Perrigo Co. (NYSE: PRGO) announced that it has received final approval from the U.S. Food and Drug Administration for its abbreviated new drug application for cetirizine hydrochloride oral solution USP, 1 mg/mL, bubble gum flavored, the store brand equivalent to Children’s Zyrtec Allergy Syrup, 1 mg/mL, bubble gum flavored.
Perrigo Co. (NYSE: PRGO) announced that its board of directors declared a quarterly dividend of 9 cents per share.
Perrigo Co. (Nasdaq: PRGO) announced that it has received tentative approval from the United States Food & Drug Administration for its abbreviated new drug application for repaglinide tablets, the generic equivalent to Prandin Tablets.
The Allegan-based generic and store-brand health products manufacturer Perrigo Co. said Monday it had purchased the ophthalmic sterile ointment and solution porfolio of Fera Pharmaceuticals LLC and its affiliates of Long Island, N.Y.
Perrigo Co. announced it has kicked off a broad industry marketing and communications campaign to raise awareness for, and consumer confidence in, generic over-the-counter medications sold at leading retailers — also known as “store brand” OTCs.
The generic drug and store brand health products maker Perrigo Co. (Nasdaq: PRGO) Wednesday reported record revenue of $919.8 million in the third fiscal quarer ended March 30, up from $778 million a year earlier.